6Beacon Strategy


The Harbert 6Beacon Strategy is a dedicated capital markets investment strategy that seeks to deliver attractive risk-adjusted absolute returns with minimal correlation to broader markets. 6Beacon offers institutional access to the Equity Capital Markets landscape. The 6Beacon Portfolio Managers look to build close and long-lasting relationships with public and private company management teams with the goal of providing capital markets expertise and guidance throughout a company’s capital raising lifecycle.

Investment Team

Jamison Yaffa
Senior Portfolio Manager

Prior to co-founding 6Beacon Capital, Jamison served as an Associate Portfolio Manager at Crestline Investors, assisting with the oversight of a global equity capital markets focused portfolio. Prior to his experience at Crestline, Mr. Yaffa worked at Balyasny Asset Management, as a syndicate trader assisting in the global capital markets process and aiding in the execution of the firm’s equity options portfolio.  He began his career as an investment banker at UBS. Mr. Yaffa graduated from the University of Connecticut with a B.A in Economics.


David Donohue
Senior Portfolio Manager

Prior to co-founding 6Beacon Capital, David worked at Balyasny Asset Management as a Director of Capital Markets. Mr. Donohue started his career at Raptor Capital Management on the trading desk. David graduated from the University of Notre Dame with a B.A. in Finance. He was a member and captain of the soccer team.


Julian Wasksal, MD
Managing Director

Prior to joining Harbert 6Beacon, Dr. Waksal completed a fellowship in hematology and oncology at The Mount Sinai Hospital, a residency in internal medicine at Weill Cornell Medical College, and served as chief resident at Memorial Sloan Kettering Cancer Center. He earned his MD at Tufts University School of Medicine and graduated magna cum laude from Vanderbilt University with a B.A. in economics and chemistry. He is board-certified in oncology and internal medicine. Dr. Waksal has designed and led numerous clinical trials and published in top tier journals including Blood and Nature-Leukemia.  Leveraging his scientific and clinical expertise, he leads our investment efforts in the biotech and healthcare space.


Jack Bryant